

1 **Type of Manuscript:** Original Research

2 **Title:** Early Short Course Corticosteroids in Hospitalized Patients with COVID-19

3 **Running Title:** Early short corticosteroids COVID-19

4 **Authors:**

5 Raef Fadel, D.O.^{1*}, Austin R. Morrison, Pharm.D.^{2*}, Amit Vahia, M.D.³, Zachary R. Smith,

6 Pharm.D.², Zohra Chaudhry, M.D.³, Pallavi Bhargava, M.D.³, Joseph Miller, M.D.⁴, Rachel M.

7 Kenney, Pharm.D.², George Alangaden, M.D.³, Mayur S. Ramesh, M.D.³, Henry Ford COVID-

8 19 Management Task Force[#]

9

10 * Raef Fadel and Austin R. Morrison contributed equally to this article.

11

12 ¹Internal Medicine, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202, USA

13 ²Pharmacy, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202, USA

14 ³Infectious Diseases, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202, USA

15 ⁴Emergency Medicine, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202, USA

16

17

18

19

20

21

22

1 **Summary**

2 In this multi-center quasi-experimental study of 213 patients, we demonstrate early short course
3 of methylprednisolone in moderate to severe COVID-19 patients reduced the composite endpoint
4 of escalation of care from ward to ICU, new requirement for mechanical ventilation, and
5 mortality.

6 **Key words:** Corticosteroids, outcomes, COVID-19, SARS-COV-2, coronavirus

7
8 **Contact information**

9 **Corresponding author**

10 Mayur Ramesh, MD

11 Henry Ford Hospital, Infectious Diseases – CFP 3

12 2799 West Grand Blvd, Detroit, MI 48202

13 mramesh1@hfhs.org

14 Phone: 313-623-2531

15
16 **Alternative author**

17 George Alangaden, MD

18 Henry Ford Hospital, Infectious Diseases – CFP 3

19 2799 West Grand Boulevard, Detroit, MI 48202

20 Email: galanga1@hfhs.org

21 Phone: 313-304-6081

22

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Abstract

Background: There is no proven antiviral or immunomodulatory therapy for COVID-19. The disease progression associated with the pro-inflammatory host response prompted us to examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19.

Methods: We conducted a single pre-test, single post-test quasi-experiment in a multi-center health system in Michigan from March 12 to March 27, 2020. Adult patients with confirmed moderate to severe COVID were included. A protocol was implemented on March 20, 2020 using early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days. Outcomes of pre and post-corticosteroid groups were evaluated. A composite endpoint of escalation of care from ward to ICU, new requirement for mechanical ventilation, and mortality was the primary outcome measure. All patients had at least 14 days of follow-up.

Results: We analyzed 213 eligible subjects, 81 (38%) and 132 (62%) in pre-and post-corticosteroid groups, respectively. The composite endpoint occurred at a significantly lower rate in post-corticosteroid group compared to pre-corticosteroid group (34.9% vs. 54.3%, $p=0.005$). This treatment effect was observed within each individual component of the composite endpoint. Significant reduction in median hospital length of stay was observed in the post-corticosteroid group (8 vs. 5 days, $p < 0.001$). Multivariate regression analysis demonstrated an independent reduction in the composite endpoint at 14-days controlling for other factors (aOR: 0.45; 95% CI [0.25 – 0.81]).

Conclusion: An early short course of methylprednisolone in patients with moderate to severe COVID-19 reduced escalation of care and improved clinical outcomes.

1 **Background**

2 As of April 9th, 2020, the United States has over 400,000 cases of confirmed coronavirus
3 disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2
4 (SARS-CoV-2) [1]. Most patients will have mild illness, but older persons and those with
5 comorbidities may develop severe disease necessitating hospitalization and intensive unit (ICU)
6 care [2, 3]. The disease pathophysiology presents in two distinct overlapping phases, the initial
7 pathogenic viral response followed by host inflammatory response with grades of severity
8 associated with distinct clinical findings [4,5]. The pathological progression in severe COVID-19
9 includes an excessive and unregulated pro-inflammatory cytokine storm resulting in
10 immunopathological lung injury, diffuse alveolar damage with the development of acute
11 respiratory distress syndrome (ARDS), and death [6-9].

12 In the absence of any proven anti-viral therapy the current clinical management is
13 primarily supportive care, supplemental oxygen, and mechanical ventilatory support [1,10].
14 Adjunctive therapy with immunomodulatory agents targeting the inflammatory cytokine storm
15 are being evaluated [5,10]. Studies of corticosteroid therapy for phylogenetically similar
16 coronavirus infections showed no benefit and potential harm [11]. Despite the frequent use in
17 treating patients with COVID-19 in China, the role of corticosteroids is undefined [3,5,10-13]. A
18 more recent observational study reported improved outcomes in patients with COVID-associated
19 ARDS that received corticosteroids [14].

20 We postulated early treatment with a short course of corticosteroids in patients with
21 COVID-19 may attenuate the excessive host respiratory and systemic inflammatory responses.

1 We report the clinical characteristics and early outcomes of patients with COVID-19 receiving
2 short courses of methylprednisolone.

3 **Methods**

4 **Study Population**

5 Consecutive patients hospitalized between March 12, 2020 through March 27, 2020 were
6 eligible for inclusion if they were 18 years of age or older, had confirmed COVID-19 infection,
7 with radiographic evidence of bilateral pulmonary infiltrates, and required oxygen by nasal
8 cannula, high-flow nasal cannula (HFNC), or mechanical ventilation. Patients were excluded if
9 they were transferred from an out-of-system hospital, died within 24 hours of presentation to the
10 ED, or were admitted for less than 24 hours. A confirmed case of COVID-19 was defined as a
11 patient that had a positive reverse-transcriptase–polymerase- chain-reaction (RT-PCR) assay for
12 SARS-CoV-2 in a nasopharyngeal sample tested by the Michigan Department of Health and
13 Human Services (MDHHS) or the Henry Ford Health System (HFHS) centralized clinical
14 microbiology laboratory. Beginning March 16, 2020, testing for hospitalized patients was
15 performed by the centralized clinical microbiology laboratory.

16 Patients were risk stratified by severity of symptoms on presentation to the hospital as
17 mild, moderate, or severe COVID-19. Patients without hypoxia or exertional dyspnea were
18 considered to have mild COVID-19. Patients with mild COVID-19 were treated with symptom
19 relief only and not admitted to the hospital. Patients who presented with infiltrates on chest
20 radiography and required supplemental oxygen by nasal cannula or HFNC were classified as
21 having moderate COVID-19. Patients who had respiratory failure requiring mechanical
22 ventilation were classified as having severe COVID-19.

1 **Study Design**

2 This was a multi-center quasi-experimental study at HFHS, comprised of five hospitals in
3 southeast and south-central Michigan. The study was approved by the institution's
4 Investigational Review Board (#13739) with waiver of consent. Patients in the pre-corticosteroid
5 protocol group from March 12, 2020 through March 19, 2020 were compared to a corticosteroid
6 protocol group that included patients from March 20, 2020 through March 27, 2020.

7 Patients in both study groups received standard care, comprised of supplemental oxygen,
8 HFNC, invasive ventilation, antibiotic agents, antiviral agents, vasopressor support, and renal-
9 replacement therapy, as determined by the primary team. Patients who progressed to ARDS were
10 managed with standard of care [15].

11 **Intervention**

12 **Pre-Corticosteroid Protocol**

13 Patients with moderate or severe disease who presented to HFHS within the first week of
14 the COVID epidemic in Detroit were initially treated with supportive care with or without a
15 combination of lopinavir-ritonavir and ribavirin or hydroxychloroquine according an institutional
16 guideline developed by Infectious Diseases Physicians and Pharmacists. The institutional
17 guidelines were developed by consensus, and based on the available literature, experience from
18 Wuhan, China and other centers around the world affected by COVID-19 before Michigan.
19 Intravenous (IV) remdesivir compassionate use was requested for eligible mechanically
20 ventilated patients. On March 17, 2020 lopinavir-ritonavir with ribavirin was removed from the
21 COVID-19 institutional protocol.[16]

22 **Corticosteroid Protocol**

1 As a result of observed poor outcomes, clinical rationale based upon immunology,
2 clinical course of COVID-19, and more recently best available evidence, the HFHS
3 corticosteroid protocol was developed (Supplementary Materials) [14,15,17]. We hypothesized
4 that early corticosteroids would combat the inflammatory cascade leading to respiratory failure,
5 ICU escalation of care, and mechanical ventilation. The corticosteroid protocol became the
6 institutional standard on March 20, 2020. Patients with confirmed influenza infection were not
7 recommended to receive corticosteroids.

8 Moderate COVID-19 was treated with hydroxychloroquine 400 mg twice daily for 2
9 doses on day 1, followed by 200 mg twice daily on days 2-5. Patients with moderate COVID-19
10 who required 4 liters or more of oxygen per minute on admission, or who had escalating oxygen
11 requirements from baseline, were recommended to receive IV methylprednisolone 0.5 to 1
12 mg/kg/day in 2 divided doses for 3 days. Patients who required ICU admission were
13 recommended to receive the above regimen of hydroxychloroquine and IV methylprednisolone
14 0.5 to 1 mg/kg/day in 2 divided doses for 3 to 7 days. ICU patients were also evaluated for
15 tocilizumab on a case-by-case basis. Oral switch was performed to prednisone at a ratio of 1 to 1
16 when determined clinically appropriate by the primary medical team.

17 **Data Collection**

18 Data was ascertained from each institution's electronic medical record and recorded in a
19 standardized electronic case report form. Demographic data, information on clinical symptoms
20 or signs at presentation, and laboratory and radiologic results during admission. All laboratory
21 tests and radiologic assessments, including plain chest radiography and computed tomography of
22 the chest, were performed at the discretion of the treating physician.

1 **Study Definitions**

2 We ascertained coexisting conditions from electronic medical record and physician
3 documentation. The National Early Warning Score (NEWS) was collected to evaluate baseline
4 illness severity based on vital signs obtained in the Emergency Department [18]. Additionally,
5 the quick Sequential Organ Failure Assessment (qSOFA) was used to evaluate severity of illness
6 of included patients based on ED vitals and examination [19]. All patients were followed for at
7 least 14 days after initial presentation. Patient data was censored on April 9, 2020.

8 **Outcome Measures**

9 *Primary Endpoint*

10 The primary composite endpoint was escalation to intensive care unit (ICU) from a
11 general medical unit (GMU), progression to respiratory failure requiring mechanical ventilation
12 after hospital admission, or in-hospital all-cause mortality. Patients directly admitted to the ICU
13 from the emergency room were evaluated for the latter two outcomes and those requiring
14 mechanical ventilation in the emergency room were evaluated for mortality.

15 *Secondary Endpoints*

16 Secondary endpoints included development and severity of ARDS, days to ventilator
17 liberation, shock, acute kidney injury (AKI), and length of hospital stay (LOS). ARDS was
18 diagnosed and classified according to the Berlin Definition [20]. AKI was diagnosed according
19 to the Kidney Disease: Improving Global Outcomes definition [21].

20 **Statistical Analysis**

21 Continuous variables were reported as median and interquartile range (IQR) and
22 compared using the Mann-Whitney test or t-test, as appropriate. Categorical data was reported as

1 number and percentage (no., %) and compared using the chi-squared test or Fisher's exact test,
2 as appropriate. No imputation was made for missing data points. The sample size was derived
3 from all eligible consecutive hospitalized patients during the study period. A two-sided $\alpha < 0.05$
4 was considered statistically significant. Bivariate and multivariable logistic regression analysis
5 was planned a-priori to test the association between the composite endpoint and exposure to the
6 corticosteroid protocol. Covariates in the bivariate analysis with a p-value < 0.2 and clinical
7 rationale were included in a multivariable regression model that was restricted to a subject-to-
8 variable ratio of 10:1. To evaluate the implementation timing of the in-house RT-PCR SARS-
9 CoV-2 testing a post-hoc sensitivity analysis were conducted on the composite outcome. A non-
10 equivalent dependent variable, receipt of, and time to empiric antibiotic therapy for pneumonia,
11 was utilized to account for potential maturation in the management of COVID-19. Statistical
12 analysis was performed using IBM SPSS version 25 (Chicago, IL) and SAS 9.4 (Cary, NC).

13 **Results**

14 Two-hundred and fifty consecutive patients were evaluated for inclusion. Ten were
15 hospitalized for 24 hours or less, 23 did not require oxygen by nasal cannula, HFNC or
16 mechanical ventilation, and four expired within 24 hours of admission. Two-hundred and
17 thirteen patients were included, 81 (38%) in the pre-corticosteroid protocol group and 132 (62%)
18 in the corticosteroid protocol group. The median age of the pre-corticosteroid protocol group and
19 corticosteroid protocol group was 64 (IQR: 51.5, 73.5) and 61 (IQR: 51, 72) years, respectively.
20 Black patients comprised 61.7% of the pre-corticosteroid protocol group and 79.5% of the
21 corticosteroid protocol group ($p=0.005$). Of the comorbid conditions evaluated, chronic
22 obstructive pulmonary disease was more frequent in the pre-corticosteroid protocol group

1 compared to the corticosteroid protocol group (18.5% vs 9.1%; $p=0.045$). The presenting
2 COVID-19 symptoms, baseline severity of illness, and other demographics were similar between
3 groups (Table I).

4 Overall, corticosteroids use was 56.8% and 68.2% in the pre-corticosteroid protocol
5 group and corticosteroid protocol group, respectively ($p=0.094$). The corticosteroid protocol
6 group had a greater proportion of corticosteroids initiated within 48 hours of presentation (12.4%
7 vs. 41.7%, $p < 0.001$). The median time to corticosteroid initiation was 5 days (IQR 3-7, range 1-
8 9) in the pre-corticosteroid protocol group and 2 days (IQR 1-3, range 0-8) in the corticosteroid
9 protocol group. The median time to hydroxychloroquine initiation was earlier in the pre-
10 corticosteroid protocol group compared to the corticosteroid protocol group (3 [IQR: 1, 4] vs. 1
11 [IQR: 0, 2] days, $p < 0.001$). Additional treatment characteristics are described in Table II.

12 The primary composite endpoint occurred at a significantly lower rate in corticosteroid
13 protocol group compared to the pre-corticosteroid protocol group (34.9% vs. 54.3%, $p=0.005$). A
14 significant reduction in each of primary composite endpoints was also noted. In the sensitivity
15 analysis sub-group, after the implementation of the in-house RT-PCR SARS-CoV-2 testing,
16 34.9% (46 of 132 patients) and 55% (33 of 60 patients) experienced the primary composite
17 endpoint in the corticosteroid protocol group and pre-corticosteroid protocol group, respectively
18 ($p=0.009$).

19 The median LOS was significantly reduced from 8 to 5 days in pre-corticosteroid
20 protocol group compared to the corticosteroid protocol group ($p < 0.001$). ARDS occurred in
21 38.3% and 26.6% in the pre-corticosteroid protocol group and corticosteroid protocol group,

1 respectively (P=0.04). After adjustment for male sex and age over 60, the corticosteroid protocol
2 was independently associated with a reduction in the composite endpoint at 14 days (aOR: 0.45;
3 95% CI [0.25 – 0.81]) (Table 2, Supplemental Materials). Outcomes at 14 days also included 9
4 (11.1%) of pre-steroid patients remaining admitted as compared to 26 (19.7%) of post-steroid
5 patients. Table III describes additional outcomes before and after implementation of the
6 corticosteroid protocol.

7 **Discussion**

8 In this quasi-experimental study, hospitalized patients with moderate to severe COVID-
9 19 that received an early short course of methylprednisolone had a reduced rate of the primary
10 composite endpoint of death, ICU transfer, and mechanical ventilation, with a number needed to
11 treat of 8 to prevent one patient transfer for mechanical ventilation. The reduction in ICU transfer
12 and requirement for mechanical ventilation represents a potential intervention to reduce critical
13 care utilization during the COVID-19 pandemic [22,23]. The median reduction of hospital LOS
14 by three days observed with the use of corticosteroids, could positively impact hospital capacity
15 during the COVID-19 surge.

16 Corticosteroids are not routinely recommended in patients with COVID-19 without an
17 alternate indication or presence of ARDS [11,15,24]. Data are conflicting; corticosteroid use in
18 previous viral respiratory illnesses have demonstrated delayed viral clearance and increased
19 mortality [11,25]. On the contrary, short course corticosteroids in some reports are beneficial and
20 safe in critically ill patients with SARS-CoV-2 and were not found to be an independent risk
21 factor of prolonged viral RNA shedding [17,26,27]. These discordant findings may be explained

1 by the observational nature of the studies, heterogeneity in patient acuity, inconsistent dosing
2 regimens and duration, and timing of initiation of therapy [10,17]. Corticosteroids were used in
3 11-35% of non-severe and 45-72% of severe COVID-19 cases in China, however the benefits
4 and risks remain undefined [2,6,12-14]. A mortality benefit (HR, 0.38: 95% CI, 0.20-0.72) with
5 the use methylprednisolone was reported in one retrospective cohort study of COVID-19 patients
6 with ARDS [14].

7 COVID-19 can progress from mild to severe illness characterized by an initial viral
8 infection phase followed by pulmonary inflammation, and then a hyper-inflammation phase
9 [4,6,9]. The pulmonary phase is associated with progressive dyspnea and radiographic findings
10 of pneumonia.[4] Symptom onset to dyspnea and ARDS development occurs between a median
11 of 5 to 7 days and 8 to 12 days, respectively [6,12,28]. The present study findings support that a
12 short course of methylprednisolone may attenuate progression to the hyper-inflammation phase
13 that requires escalation of care in patients with COVID-19. Hydroxychloroquine with or without
14 azithromycin, remdesivir, and lopinavir/ritonavir with ribavirin were prescribed at similar
15 frequency between groups. These agents have demonstrated mixed efficacy results for COVID-
16 19 in placebo controlled-trials, with hydroxychloroquine being the most promising at this time
17 [10]. Immunomodulatory agents, such as tocilizumab, were infrequently used in this study.

18 This study has several limitations. Given the pandemic nature of the disease a pragmatic
19 quasi-experimental design was used. The potential for regression to the mean and maturation is
20 an inherent limitation to all quasi-experiments. On March 16, 2020 rapid on-site RT-PCR testing
21 for SARS-CoV-2 testing was implemented, and some of the pre-steroid group experienced
22 delayed diagnosis and treatment. However, the observed association was unchanged in the

1 sensitivity analysis. A non-equivalent dependent variable, empiric antibiotic therapy for
2 pneumonia, suggested no difference in management of COVID-19. Some of the pre-
3 corticosteroid protocol group received corticosteroids after initiation of the updated COVID-19
4 institutional treatment protocol. Steroids initiated in this group were started significantly later.
5 Additionally, guideline adherence in the corticosteroid protocol group was not universal. Finally,
6 the study has a limited follow up period of 14 days, similar to other recent reports. As of April 9,
7 2020, 51 (62.9%) of patients in the pre-steroid cohort and 88 (66.7%) of patients in the post-
8 steroid cohort were discharged from the hospital. As a result, outcomes for those patients are not
9 known. Anecdotally, we observed hyperglycemia, but no severe corticosteroid related adverse
10 effects (i.e. gastrointestinal hemorrhage), and data collection is ongoing.

11 In conclusion, early use of a short course of methylprednisolone, an inexpensive and
12 readily available agent, in patients with moderate to severe COVID-19 may prevent progression
13 of disease and improve outcomes. These findings are crucial given the ongoing COVID-19
14 pandemic and ICU bed and mechanical ventilator shortages. Research is urgently needed to
15 further define the role of corticosteroids in patients with COVID-19 at a high-risk of clinical
16 deterioration, identified early in the disease course using prognostic markers or clinical
17 prediction tools.

18
19
20
21

1 **Potential conflicts of Interest:**

2 S.H. received speakers' bureau honoraria from Bayer. I.B. received speakers' bureau honoraria
3 from Gilead, ViiV and Jansszen. All others have no conflicts of interests.

4 **Financial support:**

5 None reported

6

7 **Acknowledgements**

8 #Henry Ford COVID-19 Task Force

9 Varidhi Nauriyal, M.D.^{1,2}, Jayanth Lakshmikanth, M.D.², Asif Abdul Hamed, M.D.², Owais
10 Nadeem, M.D.², Kristin Griebe, Pharm.D.³, Joseph M. Johnson, Pharm.D.³, Patrick Bradley,
11 M.D.², Junior Uduman, M.D.², Sara Hegab, M.D.², Jennifer Swiderek, M.D.², Amanda Godfrey,
12 M.D.², Jeffrey Jennings, M.D.², Jayna Gardner-Gray, M.D.⁵, Adam Ackerman, M.D.⁶, Jonathan
13 Lezotte, M.D.⁶, Joseph Ruhala, M.D.⁶, Linoj Samuel, PhD, D(ABMM).⁷, Robert J. Tibbetts,
14 Ph.D. D(ABMM) F(CCM).⁷, Indira Brar, M.D.¹, John McKinnon, M.D.¹, Geehan Suleyman,
15 M.D.¹, Nicholas Yared, M.D.¹, Erica Herc, M.D.¹, Jonathan Williams, M.D.¹, Odaliz Abreu
16 Lanfranco, M.D.¹, Anne Chen, M.D.¹, Marcus Zervos, M.D.¹
17 Eric Scher, M.D.⁴, for his courageous leadership and commitment to education in the field of
18 Academic Internal Medicine. Krishna Modi, M.D.⁴, Rebecca Bussa, Kelly Curran, M.D.⁴,
19 Abigail Entz, M.D.⁴, Hafsa Abdulla, M.D.⁴, and Charles Hammond, M.D.⁴, for data collection
20 and review. We thank the entire front-line staff members of the Henry Ford Health System for
21 dedicated and compassionate patient care during the COVID-19 outbreak.

22

1 ¹Infectious Diseases, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202;

2 ²Pulmonary Medicine, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202

3 ³Pharmacy, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202;

4 ⁴Internal Medicine, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202

5 ⁵Emergency Medicine, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202

6 ⁶Surgical Critical Care, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202

7 ⁷Pathology and Microbiology, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202

8

9

10

11

12

13

14

15

16

17

18

19

1 **References:**

- 2 1. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): cases
3 and latest updates. Accessed: April 7, 2020 ([https://www.cdc.gov/coronavirus/2019-
4 ncov/cases-updates/cases-in-us.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html))
- 5 2. Centers for Disease Control and Prevention. COVID-NET: COVID-19 associated
6 hospitalization surveillance network. Accessed: April 8, 2020
7 (https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html)
- 8 3. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China.
9 N Engl J Med. 2020 Feb 28. doi: 10.1056/NEJMoa2002032. [Epub ahead of print]
- 10 4. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A
11 Clinical-Therapeutic Staging Proposal. The Journal of Heart and Lung Transplantation. 2020
12 Mar 20. <https://doi.org/10.1016/j.healun.2020.03.012> [Epub ahead of print]
- 13 5. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of
14 people with severe coronavirus disease 2019 (COVID-19): The experience of clinical
15 immunologists from China. Clinical Immunology. 2020 Mar 25:108393.
- 16 6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
17 coronavirus in Wuhan, China. The Lancet. 2020 Feb 15;395(10223):497-506. doi:
18 10.1016/S0140-6736(20)30183-5.
- 19 7. Tian S, Hu W, Niu L, et al. Pulmonary pathology of early phase 2019 novel coronavirus
20 (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020 Feb 28. pii:
21 S1556-0864(20)30132-5. doi: 10.1016/j.jtho.2020.02.010. [Epub ahead of print]

- 1 8. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute
2 respiratory distress syndrome. *Lancet Respir Med*. 2020 Feb 18. pii: S2213-2600(20)30076-
3 X. doi: 10.1016/S2213-2600(20)30076-X. [Epub ahead of print]
- 4 9. Zhou Y, Fu B, Zhang X, et al. Pathogenic T cells and inflammatory monocytes incite
5 inflammatory storm in Severe COVID-19 patients. *National Science Review*, nwaa041,
6 <https://doi.org/10.1093/nsr/nwaa041>
- 7 10. McCreary EK, Pouge JM. COVID-19 Treatment: A Review of Early and Emerging Options.
8 *Open Forum Infectious Diseases*. 2020. ofaa105. <https://doi.org/10.1093/ofid/ofaa105>
- 9 11. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment
10 for 2019-nCoV lung injury. *The Lancet*. 2020 Feb 15;395(10223):473-5.
- 11 12. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019
12 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020 Feb 7. doi:
13 10.1001/jama.2020.1585. [Epub ahead of print]
- 14 13. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-
15 CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
16 *Lancet Respir Med*. 2020 Feb 24. pii: S2213-2600(20)30079-5.
- 17 14. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress
18 Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan,
19 China. *JAMA Intern Med*. 2020 Mar 13. doi: 10.1001/jamainternmed.2020.0994. [Epub
20 ahead of print]

- 1 15. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the
2 Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). *Crit Care*
3 *Med.* 2020 Mar 27. doi: 10.1097/CCM.0000000000004363. [Epub ahead of print]
- 4 16. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with
5 Severe Covid-19. *N Engl J Med.* 2020 Mar 18. doi: 10.1056/NEJMoa2001282. [Epub ahead
6 of print]
- 7 17. Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. *The*
8 *Lancet.* 2020 Feb 29;395(10225):683-4.
- 9 18. Smith GB, Prytherch DR, Meredith P, et al. The ability of the National Early Warning Score
10 (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care
11 unit admission, and death. *Resuscitation.* 2013 Apr;84(4):465-70.
- 12 19. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis: For the
13 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA.*
14 2016 Feb 23;315(8):762-74.
- 15 20. Ranieri V, Rubenfeld GD, Thompson B, et al. Acute respiratory distress syndrome: the
16 Berlin Definition. *JAMA.* 2012 Jun 20;307(23):2526-33.
- 17 21. Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes
18 (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute
19 kidney injury. *Kidney International Supplements.* 2012 Jan 1;2(1):1-38.
- 20 22. White DB, Lo B. A Framework for Rationing Ventilators and Critical Care Beds During the
21 COVID-19 Pandemic. *JAMA.* 2020 Mar 27. doi: 10.1001/jama.2020.5046. [Epub ahead of
22 print]

- 1 23. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators and
2 Personal Protective Equipment during the Covid-19 Pandemic. *N Engl J Med*. 2020 Mar 25.
3 doi: 10.1056/NEJMp2006141. [Epub ahead of print]
- 4 24. World Health Organization. Clinical management of severe acute respiratory infection
5 (SARI) when COVID-19 disease is suspected: Interim guidance V 1.2.
6 [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected)
7 [infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected) (accessed 4/3/2020).
- 8 25. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill
9 Patients with Middle East Respiratory Syndrome. *Am J Respir Crit Care Med*. 2018 Mar
10 15;197(6):757-767.
- 11 26. Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with
12 glucosteroids: the Guangzhou experience. *Chest*. 2006 Jun;129(6):1441-52.
- 13 27. Xu K, Chen Y, Yhan J, et al. Factors associated with prolonged viral RNA shedding in
14 patients with COVID-19. *Clinical Infectious Diseases* 2020. ciaa351.
15 <https://doi.org/10.1093/cid/ciaa351>.
- 16 28. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
17 with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020 Mar
18 28;395(10229):1054-1062.
- 19
20
21

1 Table I. Baseline Demographics and Clinical Characteristics of Study Patients

Characteristics	Total (n=213)	Pre-Protocol (n=81)	Post-Protocol (n=132)	p-value
Demographics				
Median age (IQR) - yr	62 (51-62)	64 (51.5-3.5)	61 (51-72)	0.400
Male sex – no. (%)	109 (51.2)	41 (50.6)	68 (51.5)	0.899
Black race – no. (%)	155 (72.8)	50 (61.7)	105 (79.5)	0.004
Median body mass index (IQR) - kg/m ²	32 (27.3-38.7)	30 (25-39)	33.2 (28.9-38.5)	0.007
Coexisting conditions – no. (%)				
Asthma	33 (15.5)	16 (19.8)	17 (12.9)	0.180
Chronic kidney disease	98 (46)	41 (51.9)	57 (43.5)	0.240
Chronic obstructive pulmonary disease	27 (12.7)	15 (18.5)	12 (9.1)	0.045
Congestive heart failure	26 (12.2)	10 (12.5)	16 (12.2)	0.951
Coronary artery disease	38 (17.8)	18 (22.2)	20 (15.2)	0.192
Diabetes	105 (49.3)	37 (45.7)	68 (51.5)	0.411
Hypertension	158 (74.2)	62 (76.5)	96 (72.7)	0.925
Malignancy	24 (11.3)	11 (13.6)	13 (9.9)	0.405
Smoking history	88 (41.3)	40 (49.4)	48 (36.4)	0.0615
Symptoms				
Cough – no. (%)	158 (74.2)	62 (76.5)	96 (72.7)	0.536
Fever – no. (%)	150 (70.4)	57 (70.4)	93 (70.5)	0.989
Myalgia – no. (%)	85 (39.9)	32 (39.5)	53 (40.2)	0.926
Shortness of breath – no. (%)	148 (69.5)	50 (61.7)	98 (74.2)	0.054
Median duration of symptoms (IQR) - days	5 (3-7)	5 (2-7)	6 (3-7)	0.107
Severity of illness in emergency department (ED)				
Median qSOFA (IQR)	1 (0-1)	1 (0-1)	1 (0-1)	0.850
Median NEWS (IQR)	7 (4-10)	7 (4-10)	7 (4-9)	0.668
Requiring mechanical ventilation in ED – no. (%)	22 (10.3)	10 (12.3)	12 (9.1)	0.448
Direct admission to ICU – no. (%)	26 (12.2)	11 (13.6)	15 (11.4)	0.631

2 *IQR denotes Interquartile range, NEWS denotes National Early Warning Score, qSOFA

3 denotes quick Sequential Organ Failure Assessment (qSOFA), ED denotes Emergency

4 Department, ICU denotes intensive care unit

5 Table II. Treatments Received by Patients Pre-Corticosteroid and Corticosteroid Protocol

6 Groups

Treatment	Total (n=213)	Pre-Protocol (n=81)	Post-Protocol (n=132)	p-value
Antimicrobials				
Empiric antibiotic prescribed for pneumonia – no. (%)	163 (76.5)	65 (80.2)	98 (74)	0.316
Median time to empiric antibiotics (IQR) – days	1 (0-1)	1 (0-1)	0 (0-1)	0.631
Median duration of antimicrobials (IQR) - days	4 (2-5)	5 (3-5)	3 (2-5)	0.009
Hydroxychloroquine use - no. (%)	161 (75.6)	57 (70.4)	104 (78.8)	0.167
Median time to hydroxychloroquine initiation (IQR) - days	2 (1-3)	3 (1-4)	1 (0-2)	0.126
Lopinavir/ritonavir and ribavirin use - no. (%)	10 (4.7)	9 (11.1)	1 (0.76)	0.001
Remdesivir use – no. (%)	5 (2.3)	5 (6.2)	0 (0)	0.004
Tocilizumab use – no. (%)	14 (6.6)	8 (10.1)	6 (4.5)	0.126
Corticosteroid treatment				
Corticosteroids received at any time - no. (%)	136 (63.8)	46 (56.8)	90 (68.2)	0.094
Corticosteroids received in first 48 hours - no. (%)	65 (30.5)	10 (12.4)	55 (41.7)	<0.001
Median time to steroid initiation from admission (IQR) – days	2 (1-4)	5 (3-7)	2 (1-3)	<0.001
Median methylprednisolone dose (IQR) – mg	40 (40-50)	40 (40-50)	40 (35-50)	0.851
Median duration of corticosteroids (IQR) – days	3 (3-3)	3 (3-3)	3 (3-3)	0.812

1 *IQR denotes Interquartile range

2

3

4

5 **Table III. Outcomes in the Pre-Corticosteroid and Corticosteroid Protocol Groups**

	Pre-Protocol (n=81)	Post-Protocol (n=132)	Odds Ratio (CI)	p-value
Primary Outcome				


Primary composite outcome – no. (%)	44 (54.3)	46 (34.9)	0.45 (0.26 – 0.79)	0.005
Death – no. (%)	21 (26.3)	18 (13.6)	0.45 (0.22 – 0.91)	0.024
Respiratory failure requiring mechanical ventilation – no. (%)*	26 (36.6)	26 (21.7)	0.47 (0.25-0.92)	0.025
Escalation from GMU to ICU – no. (%) ⁺	31 (44.3)	32 (27.3)	0.47 (0.25 – 0.88)	0.017
Secondary Outcomes				
Overall mechanical ventilation – no. (%)	36 (44.4)	38 (28.8)	0.51 (0.28 – 0.90)	0.020
ARDS – no. (%)	31 (38.3)	33 (26.6)		0.040
Mild	3 (3.7)	1 (0.76)		0.125
Moderate	8 (9.9)	9 (6.8)		0.307
Severe	20 (24.7)	23 (17.4)		0.201
Median duration of mechanical ventilation (IQR) - days	8 (4-13)	7 (4-9)		0.558
Median time to extubation (IQR) – days	8 (4-13)	7 (4-9)		0.558
Shock – no. (%)	19 (23.5)	17 (12.6)		0.069
Acute kidney injury – no. (%)	42 (51.9)	59 (44.7)		0.310
Median hospital length of stay (IQR) - days	8 (5-14)	5 (3-7)		<0.001
Discharged from hospital – no. (%)	51 (62.2)	88 (66.7)		0.584
Remain hospitalized – no. (%)	9 (11.1)	26 (19.7)		0.102
Remain intubated – no. (%)	7 (8.6)	13 (9.8)		0.771

1 CI denotes confidence interval, ICU denotes intensive care unit, GMU denotes general medical
2 unit, ARDS denotes acute respiratory distress syndrome, IQR denotes Interquartile range

3 *A total of 10 and 12 patients were not included in this analysis because they required
4 mechanical ventilation in the emergency department in the pre-corticosteroid and corticosteroid
5 group, respectively.

6 +A total of 11 and 15 patients were not included in this analysis because they were directly
7 admitted to the intensive care unit in the pre-corticosteroid and corticosteroid group,
8 respectively.

Figure 1. Number of Patients Screened and Included in the Trial



Supplemental Materials

Table 1. Baseline laboratory tests for the pre- and post- corticosteroid protocol populations*

Laboratory test – median (IQR)	Pre-protocol	Post-protocol
White blood cell count ($\times 10^9$ per liter)	5.8 (4.1-7.6)	5.55 (4.2-6.9)
Absolute lymphocyte count ($\times 10^9$ per liter)	0.8 (0.6-1.1)	0.8 (0.6-1.2)
Absolute monocyte count ($\times 10^9$ per liter)	0.4 (0.3-0.7)	0.4 (0.3-0.7)
Platelets (g/dL)	185 (148-228)	167.5 (141-213)
Lactate Dehydrogenase, serum (units/L)	329 (254-489)	331 (254-414)
C-reactive protein (mg/dL)	9.8 (6-13.1)	8.8 (3.4-12.8)
Creatinine kinase (IU/L)	115 (57-326)	204 (99.5-498)
Ferritin, serum (ng/mL)	504 (186-1318)	517 (232-1064)
Fibrinogen, plasma (mg/dL)	579 (484-653)	568 (482-628)
D-dimer (ug/mL)	1.14 (0.52-2.44)	1.04 (0.64-1.78)
Procalcitonin (ug/L)	0.15 (0-0.43)	0.16 (0-0.38)
High sensitivity troponin (ng/mL)	0 (0-39)	0 (0-26)
Triglycerides (mg/dL)	140 (100-201)	123 (109-153)
Interleukin-6 (pg/mL)	8 (0-33)	8 (0-16)
Lactic acid, plasma (mg/dL)	1.2 (1-1.8)	1.2 (1-1.75)

*Laboratory values not reflective of entire study population as some patients without complete panel. IQR denotes interquartile range

Table 2. Multivariate Logistic Regression for Effect on Composite Endpoint at 14 Days

Covariate	Adjusted odds ratio	p-value
Corticosteroid protocol	0.45 (0.25 – 0.81)	0.007
Male gender	2.20 (1.23 – 3.91)	0.008
Age greater than 60 (years)	1.97 (1.1 – 3.54)	0.022

Figure 1. Management and Treatment of COVID-19 Cases Guideline



**Henry Ford Hospital Division of Infectious Diseases
Management and Treatment of COVID-19 Cases**

All confirmed COVID-19 inpatients **require Infectious Diseases consultation** for management. For testing recommendations, please refer to **SARS-CoV-2 (COVID-19) Testing Criteria** from HFHS infection prevention and control.

Currently, there are no FDA approved therapies to treat COVID-19. Some medications have demonstrated in vitro, animal, or very limited clinical safety and efficacy data in other coronaviruses (e.g. SARS and MERS). The Division of Infectious Diseases is coordinating research/compassionate use remdesivir. The below treatments should be started immediately once COVID test is positive (when indicated), pending remdesivir availability. **Preemptively starting COVID medications prior to return of test results is not recommended due to limited medication supply unless there is high suspicion based upon clinical judgement and patient characteristics.** These guidelines are interim recommendations and may change according to drug availability and new data published. Supportive care and infection control measures are indicated for all hospitalized patients.

Initial labs for all inpatients (see below for ongoing treatment monitoring):

- Suspected or confirmed patients: CBC with differential, BMP, magnesium, ferritin, liver profile, bilirubin, total, procalcitonin, CPK, D-dimer, CRP, LDH, high sensitivity troponin
- Draw upon admission to **ICU**: Triglyceride, IL-6, DIC panel (in addition to labs listed above if not previously ordered)
- Baseline EKG

Treatment for COVID Patients			
	Mild symptoms, outpatient	Moderate symptoms, hospitalized	Severe, hospitalized
Characteristics	Cough, fever, myalgias On Room air / baseline SAO ₂ 94% or above No radiographic evidence of pulmonary infiltrates	Supplemental oxygen use or Sao₂ less than 94% , fever of ≥ 36.6°C armpit, ≥ 37.2 °C oral, or ≥ 37.8°C rectal, radiographic evidence of pulmonary infiltrates	Respiratory failure requiring mechanical ventilation Cough, fever, myalgias
Recommended treatment	Social distancing recommended <u>Consider OTC Symptom relief</u> Cough: -vaporizer or humidifier -dextromethorphan (dry	*Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 4 days OR Remdesivir : Requires patient	*Hydroxychloroquine 400mg PO BID x 2 doses, then 200 mg PO BID x 4 days OR Remdesivir : Expanded access

	cough) -guaifenesin (productive cough) Fever: Acetaminophen	informed consent for clinical trial. Not an FDA approved therapy	Requires patient informed consent. Not an FDA approved therapy
--	--	--	--

Treatment for COVID Patients (continued)			
	Mild symptoms, outpatient	Moderate symptoms, hospitalized	Severe, hospitalized
Adjunctive Therapy		<ul style="list-style-type: none"> - Steroids routinely not recommended unless indicated for another comorbidity (e.g. COPD) <p>New supplemental oxygen \geq 4 L or escalating oxygen requirements from baseline</p> <ul style="list-style-type: none"> - Recommend low dose methylprednisolone with a short course (e.g. 0.5-1 mg/kg/day based on actual body weight divided in 2 doses for 3 days) - If severe hypoxia with continued supplemental oxygen requirement on day 3, consider extending methylprednisolone to a total duration of 5 to 7 days 	<ul style="list-style-type: none"> - Steroids routinely not recommended unless indicated for another comorbidity (e.g. COPD) <p>Mechanical ventilation</p> <ul style="list-style-type: none"> - Recommend low dose methylprednisolone with a short course (e.g. 0.5-1 mg/kg/day based on actual body weight divided in 2 doses for 3 days) - If severe hypoxia with continued supplemental oxygen requirement on day 3, consider extending methylprednisolone to a total duration of 5 to 7 days <p>Additional immunomodulator usage will be determined on a case-by-case basis with the ICU and ID COVID team</p>

NOTES: If influenza testing was done and is **positive, steroids are not recommended.**

#Consider a dose maximum of methylprednisolone 80 mg IV every 12 hours for obese patients.

When clinically appropriate for oral switch, convert methylprednisolone 1:1 to oral prednisone.

Monitoring Parameters:

- Hydroxychloroquine: Cardiotoxicity, Torsade de Pointes, depression, psychosis. Maintain potassium at least 4 mEq/L, and magnesium at least 2 mEq/L. **Refer to QT monitoring appendix.**
- Remdesivir: Phlebitis, Constipation, Nausea, Headache, Bruising, Liver Function test abnormalities. Obtain daily BMP and LFTs.